Compass Therapeutics, Inc.
CMPX
NASDAQ·Healthcare·Biotechnology·Mkt cap $428.6M
$2.38
▲ +0.42%
P/E
-5.67
Mkt Cap
$428.6M
52-Wk Range
$1.61–$6.88
52-Week Range
$1.61 - $6.88
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 30.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary bispecific antibody platform technology enabling dual-pathway targeting
- Focused pipeline addressing validated oncology mechanisms with differentiation potential
- Clinical-stage assets with potential for significant market opportunities in large cancer indications
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Clinical trial progression and regulatory milestones for CTX-009, CTX-471, and CTX-8371
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+17.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CMPX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 6, 2026
Reported EPS of -$0.13 vs -$0.11 consensus (-17.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-17.5%
Revenue trend · last 8Q
—
—
—
-100%
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
6 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Jun 4, 2026
vs Industry
How CMPX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related